Acquisition by Eric Devroe of 10000 shares of Acrivon Therapeutics at 1.04 subject to Rule 16b-3
| ACRV Stock | 7.58 0.06 0.80% |
Slightly above 52% of Acrivon Therapeutics,'s investor base is interested to short. The analysis of the overall investor sentiment regarding Acrivon Therapeutics, Common suggests that many traders are impartial. Acrivon Therapeutics,'s investing sentiment can be driven by a variety of factors including economic data, Acrivon Therapeutics,'s earnings reports, geopolitical events, and overall market trends.
Acrivon |
Filed transaction by Acrivon Therapeutics Common Officer: Chief Operating Officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Acrivon Therapeutics,'s cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Acrivon Therapeutics,'s relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Acrivon Therapeutics, Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Acrivon Therapeutics, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Acrivon Therapeutics, Fundamental Analysis
We analyze Acrivon Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acrivon Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acrivon Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Acrivon Therapeutics, is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Acrivon Therapeutics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acrivon Therapeutics, stock to make a market-neutral strategy. Peer analysis of Acrivon Therapeutics, could also be used in its relative valuation, which is a method of valuing Acrivon Therapeutics, by comparing valuation metrics with similar companies.
Peers
Acrivon Therapeutics, Related Equities
| ANTX | AN2 Therapeutics | 21.90 | ||||
| OPT | Opthea | 10.81 | ||||
| ADAG | Adagene | 1.30 | ||||
| PMVP | Pmv Pharmaceuticals | 1.25 | ||||
| RZLT | Rezolute | 1.00 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
| MOLN | Molecular Partners | 0.17 | ||||
| AVTE | Aerovate Therapeutics | 0.38 | ||||
| ANAB | AnaptysBio | 0.64 | ||||
| MLYS | Mineralys Therapeutics, | 2.59 |
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.